Indian Bank’s Q3FY26 performance underscores a phase of measured consolidation rather than aggressive expansion.

Dr Reddy’s Laboratories is navigating a critical transition phase as legacy gains from gRevlimid taper off, even as the company lays the groundwork for its next multi-year growth cycle.

ICICI Direct has reiterated its BUY recommendation on SRF Limited, setting a 12-month target price of Rs 3,315, implying an upside of 21 percent from current levels.

ITC Hotels Limited has delivered a resilient and broad-based performance in Q3FY26, reinforcing confidence in its medium-term growth trajectory.

Tech Mahindra is entering a decisive phase of recovery after posting its strongest operational quarter in nearly three years.

ICICI Securities has reiterated its BUY rating on Axis Bank, projecting a resilient earnings trajectory despite a deliberate trade-off between net interest margin (NIM) and balance sheet expansion.